Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America

NCT02623725 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT02623725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02623725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 2
Overall status
Completed
Start date
April 14, 2016
Completion date
October 28, 2018
Enrollment
251 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever, dengue hemorrhagic fever